CytoMed Therapeutics Total Current Liabilities

The latest total current liabilities for GDTC is $710K as of December 2025. That compares with $440K in the prior-year period — up 59.5% year over year. Investors often review this figure alongside CytoMed Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GDTC's total current liabilities moved from $440K to $710K — a 59.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CytoMed Therapeutics's operating scale or balance-sheet position.

A total current liabilities figure of $710K for GDTC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GDTC's total current liabilities ($710K), review year-over-year change from $440K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.